DiaMedica Therapeutics (DMAC) Net Income (2018 - 2026)

DiaMedica Therapeutics' Net Income history runs 9 years deep, the most recent figure standing at -$10.0 million for Q1 2026.

• On a quarterly basis, Net Income fell 30.3% year-over-year to -$10.0 million in Q1 2026; TTM through Mar 2026 was -$30.2 million, a 11.71% decrease from a year earlier, with the FY2025 full-year figure at -$27.8 million, down 13.84% from the prior year.
• Net Income eased to -$10.0 million in Q1 2026 per DMAC's latest filing, from -$3.8 million in the prior quarter.
• Across five years, Net Income topped out at -$3.1 million in Q3 2022 and bottomed at -$10.0 million in Q1 2026.
• The 5-year median for Net Income is -$5.2 million (2024), against an average of -$5.6 million.
• Across the five-year window, Net Income plunged 53.07% in 2024 and surged 51.89% in 2025, its largest moves.
• Year by year, Net Income stood at -$3.8 million in 2022, then slumped by 37.59% to -$5.2 million in 2023, then tumbled by 53.07% to -$7.9 million in 2024, then surged by 51.89% to -$3.8 million in 2025, then tumbled by 164.19% to -$10.0 million in 2026.
• Per Business Quant, the three latest DMAC Net Income figures stand at -$10.0 million (Q1 2026), -$3.8 million (Q4 2025), and -$8.6 million (Q3 2025).